NFKB1 Antibody

NFKB1

DKFZp686C01211 antibody; DNA binding factor KBF1 antibody; DNA binding factor KBF1 EBP1 antibody; DNA-binding factor KBF1 antibody; EBP 1 antibody; EBP-1 antibody; EBP1 antibody; KBF1 antibody; MGC54151 antibody; nf b antibody; NF kappa B antibody; NF kappaB antibody; NF kappabeta antibody; NF kB1 antibody; NF-kappaB antibody; NFkappaB antibody; NFKB 1 antibody; NFKB p105 antibody; NFKB p50 antibody; NFKB-p105 antibody; Nfkb1 antibody; NFKB1_HUMAN antibody; Nuclear factor kappa B DNA binding subunit antibody; Nuclear factor kappa-B antibody; Nuclear factor kappa-B, subunit 1 antibody; Nuclear factor NF kappa B p105 subunit antibody; Nuclear factor NF kappa B p50 subunit antibody; Nuclear factor NF-kappa-B p50 subunit antibody; Nuclear factor of kappa light chain gene enhancer in B cells 1 antibody; Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody; p105 antibody; p50 antibody; p84/NF-kappa-B1 p98 antibody; Transcription factor NFKB1 antibody

Recombinant Human Nuclear factor NF-kappa-B p105 subunit protein (1-961AA)

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling, active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.

>95%, Protein G purified

Cell Biology

Recombinant Human Nuclear factor NF-kappa-B p105 subunit protein (1-961AA)